Remove News Regulation-Policy
article thumbnail

Drug pricing: PMPRB announces framework for new guidelines consultation

Pharma in Brief

The Patented Medicine Prices Review Board ( PMPRB ) has announced a framework for the launch of its consultation on new guidelines, beginning with a scoping paper to be published in advance of Policy Roundtable sessions to be held December 5 (English) and December 6 (French), 2023.

article thumbnail

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible

The Pharma Data

laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. This site is governed solely by applicable U.S. Your use of the information on this site is subject to the terms of our Legal Notice.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

0001567619-21-009229 | 13F-NT | Johnson & Johnson

The Pharma Data

laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. This site is governed solely by applicable U.S. Your use of the information on this site is subject to the terms of our Legal Notice.

article thumbnail

WCG Clinical Announces Relaunch of FDAnews as the Premier Source for Drug and Device Insights

WCG Clinical

Each business day, the new FDAnews will deliver precisely what pharmaceutical and medical device manufacturers have told us they need to know about regulatory compliance and good manufacturing practices,” said Terri Moench, RPh, MS, President, Research Solutions for WCG. Learn more at fdanews.com.

article thumbnail

The emergence of tranq amidst the fentanyl crisis

Pharmaceutical Technology

“Xylazine started showing up in the dope in Philadelphia around 2010 and recently started to spread across the US, says Jon Zibbell, PhD, a senior public health scientist at RTI International, a non-profit research institute in North Carolina that provides data and analysis to inform public policy.”

Drugs 278
article thumbnail

This week in drug discovery (1-5 January) 

Drug Discovery World

News round-up for 1-5 January by DDW Digital Content Editor Diana Spencer. The start of 2024 has seen quite a bit of regulatory activity, with the UK MHRA’s launch of a new procedure for assessing drugs, along with significant regulatory approvals for therapeutics for cytomegalovirus, melanoma, amyloidosis and multiple sclerosis.

Drugs 52
article thumbnail

Grand Rounds October 21, 2022: Disinformation, Cyberthreat, and Choice: Protecting Patients and Clinical Research From the Digital Triple Threat (Eric Perakslis, PhD; Andrea Downing)

Rethinking Clinical Trials

Should social media for teenagers be regulated like a digital therapeutic, given how addictive they are and the behavior modification. In a recent paper, Health advertising on Facebook: Privacy and Policy Considerations, patients download their raw data, and found who was tracking them across the internet. Case study: The U.K.